Vemurafenib and cutaneous adverse events--report of five cases.
An Bras Dermatol
; 90(3 Suppl 1): 242-6, 2015.
Article
en En
| MEDLINE
| ID: mdl-26312729
Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedades de la Piel
/
Neoplasias Cutáneas
/
Sulfonamidas
/
Proteínas Proto-Oncogénicas B-raf
/
Indoles
/
Melanoma
/
Antineoplásicos
Aspecto:
Patient_preference
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
An Bras Dermatol
Año:
2015
Tipo del documento:
Article
Pais de publicación:
España